Bioversys Says Patent Claims For Its BV100 Drug Candidate Have Been Granted In China
March 31 (Reuters) - BIOVERSYS AG BIOV.S:
PATENT AROUND BIOVERSYS' BV100 DRUG CANDIDATE HAS BEEN GRANTED, PROTECTING PROPRIETARY RIFABUTIN IV FORMULATION TECHNOLOGY IN CHINA
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Why AMD Stock Popped: 12-Day Winning Rally Signals CPU Renaissance in Agentic AI Push

Why Is Ethereum Stalling While Bitcoin Surges? Will It Ever Reach $10,000?

APLD Stock Surge: How CoreWeave Lease Amendments and Delta Forge 1 Milestones De-risk the Bull Case

TSLA Q1 Earnings Preview: Tesla Snaps 8-Week Slump—Now Buy the Dip or Wait?

GPT-Rosalind Sparks CRO Sector Slump: Should Investors Buy the Dip or Exit Amid AI Drug R&D Impact?

Tradingkey







